22775-37-7

Usage

Uses

Used in Pharmaceutical Chemistry:
3,5-Dichloro-2-methoxybenzoic acid is used as a key intermediate in the synthesis of various bioactive compounds, contributing to the development of new therapeutic agents. Its unique structure allows for the creation of molecules with potential medicinal applications.
Used in Chemical Research:
3,5-DICHLORO-2-METHOXYBENZOIC ACID serves as a subject of study in chemical research, where its properties and reactivity are explored. This research can lead to a better understanding of its potential uses and interactions with other molecules, further expanding its applications in the field of chemistry.
Used in Material Science:
3,5-Dichloro-2-methoxybenzoic acid may also find applications in material science, where its structural features could be leveraged to develop new materials with specific properties, such as improved stability or reactivity in various chemical processes.

InChI:InChI=1/C8H6Cl2O3/c1-13-7-5(8(11)12)2-4(9)3-6(7)10/h2-3H,1H3,(H,11,12)

Upstream product

• 13334-73-1 2,4-dichloro-6-methyl-anisole 
• 579-75-9 2-Methoxybenzoic acid 
• 64122-23-2 methyl 3,5-dichloro-2-methoxybenzoate 
• 7697-37-2 nitric acid 
• 320-72-9 3,5-dichlorosalicylic acid 
• 77-78-1 dimethyl sulfate 
• 1570-65-6 4,6-dichloro-2-methylphenol 
• 74-88-4 methyl iodide 
• 95-48-7 ortho-cresol 
• 69-72-7 salicylic acid 

Downstream Products

• 64122-23-2 methyl 3,5-dichloro-2-methoxybenzoate 
• 5213-08-1 3,5-dichloro-2-methoxybenzoyl chloride 
• 174417-14-2 ethyl 4-(3,5-dichloro-2-hydroxybenzoyl)pyrrole-2-carboxylate 
• 134024-43-4 (S)-2-[(3,5-dichloro-2-methoxybenzamido)-methyl]-1-ethylpyrrolidine 
• 69640-33-1 2-(3,5-dichloro-2-methoxyphenyl)-1H-pyrrole 
• 121789-62-6 2-(3,5-Dichlor-2-hydroxyphenyl)-1H-pyrrol 
• 121789-41-1 1-(3,5-Dichlor-2-methoxyphenyl)-1,4-butandion 
• 121789-29-5 1-(3,5-Dichlor-2-methoxyphenyl)-3-(1,3-dioxan-2-yl)-1-propanon 
• 121789-57-9 2,3,4-tribromo-5-(3,5-dichloro-2-methoxyphenyl)-1H-pyrrole 
• 121789-63-7 2,3,4-tribromo-5-(3,5-dichloro-2-hydroxyphenyl)-1H-pyrrole 
• 75230-24-9 N-Cyclooctyl-N'-(3,5-dichloro-2-methoxy-benzoyl)-guanidine; hydrochloride 
• 205320-03-2 3,5-Dichloro-2,N-dimethoxy-N-methyl-benzamide 
• 1314114-47-0 3,5-dichloro-N-(3-chloro-4-(naphthalen-2-yloxy)phenyl)-2-methoxybenzamide 

Relevant academic research and scientific papers

Discovery and structure-activity relationships of modified salicylanilides as cell permeable inhibitors of poly(ADP-ribose) glycohydrolase (PARG)

The metabolism of poly(ADP-ribose) (PAR) in response to DNA strand breaks, which involves the concerted activities of poly(ADP-ribose) polymerases (PARPs) and poly(ADP-ribose) glycohydrolase (PARG), modulates cell recovery or cell death depending upon the level of DNA damage. While PARP inhibitors show high promise in clinical trials because of their low toxicity and selectivity for BRCA related cancers, evaluation of the therapeutic potential of PARG is limited by the lack of well-validated cell permeable inhibitors. In this study, target-related affinity profiling (TRAP), an alternative to high-throughput screening, was used to identify a number of druglike compounds from several chemical classes that demonstrated PARG inhibition in the low-micromolar range. A number of analogues of one of the most active chemotypes were synthesized to explore the structure-activity relationship (SAR) for that series. This led to the discovery of a putative pharmacophore for PARG inhibition that contains a modified salicylanilide structure. Interestingly, these compounds also inhibit PARP-1, indicating strong homology in the active sites of PARG and PARP-1 and raising a new challenge for development of PARG specific inhibitors. The cellular activity of a lead inhibitor was demonstrated by the inhibition of both PARP and PARG activity in squamous cell carcinoma cells, although preferential inhibition of PARG relative to PARP was observed. The ability of inhibitors to modulate PAR metabolism via simultaneous effects on PARPs and PARG may represent a new approach for therapeutic development.

Acyl derivatives of 2-aminobenzimidazole and their fungicide activity

Procedures have been developed for the preparation of methyl 2-benzimidazolylcarbamate, 2-acetylaminobenzimidazole, 2- benzoylaminobenzimidazole, 2-(3,5-dibromo-2-hydroxybenzoylamino)benzimidazole, 1-(3,6-dichloro-2-methoxybenzoyl)-2-aminobenzimidazole, 2-(3,5-dichloro-2- hydroxybenzoylamino)benzimidazole, 2-(3,5-dichloro-2-methoxybenzoylamino) benzimidazole, and 1-(3,5,6-trichloro-2-methoxybenzoyl)-2-aminobenzimidazole. The synthesized compounds have been tested for fungicide activity.

Synthesis of ω-Fluoroalkoxy and Alkoxy Derivatives of Raclopride: Evaluation as Radioligands for PET study of Cerebral Dopamine D2 Receptors

A series of analogues of the dopamine D2 receptor antagonist raclopride were evaluated as radiopharmaceuticals for positron emission tomography (PET). In vitro assays indicate that the D2 affinity of the ligands are descreased by replacement of the 2-methoxy group of raclopride with ω-fluoroalkoxy substituents, and increased by removal of the 6-hydroxy substituent. The 2-fluoroethoxy derivative of deshydroxy raclopride, [(S)-2-[(3,5)-dichloro-2-(2'-fluoroethoxy)benzamido)-methyl]-1-ethylpyrrolidine], exhibited a D2 affinity (Ki = 12nM) close to that of raclopride itself (Ki = 9.5 nM). A one-step radiosynthesis of the fluorine-18 labeled analogue of this ligand with specific radioactivity > 2 Ci/μmol and 35 percent radiochemical yield (decay-corrected) was developed; there was poor receptor-specific localization of this radioligand in vivo in rats, however. These results underscore the inadequacy of in vitro receptor assays as the sole screening test for PET radiopharmaceuticals. Future development of this series of ligands should emphasize placement of the fluorine-18 label at an aromatic site remote from the intramolecular hydrogen-bonding sites necessary for receptor-active conformations

Marine Bacteria, I. - Synthesis of Pentabromopseudiline, a Cytotoxic Phenylpyrrole from Alteromonas luteo-violaceus

A new synthesis of 2,3,4-tribromo-5-(3,5-dibromo-2-hydroxyphenyl)pyrrole (1a, pentabromopseudiline), an antibiotic, enzymeinhibitory and cytotoxic active constituent of the marine bacterium Alteromonas luteo-violaceus, is described.For investigation of structure-activity relationships further 2-phenylpyrroles are investigated.Key step in their synthesis is the Grignard reaction of 2-(1,3-dioxan-2-yl)ethylmagnesium bromide (9d) with benzoyl chlorides yielding γ-phenyl-γ-ketoaldehydes 24, and the Paal-Knorr cyclisation of the latter. - Key Words: Alteromonas luteo-violaceus / Bromopyrrole / Marine bacteria / Pentabromopseudiline